Multi-Center Clean Air Randomized Controlled Trial in COPD
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- JHSPH Center for Clinical Trials
- Study ID
- NCT06376994
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
Eligibility Criteria
- Sex
- ALL
- Age
- 40 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Air cleaner — DEVICEThe intervention is two active air cleaners with high efficiency particulate air (HEPA) filters which remove PM, as well as activated carbon filters to remove NO2 (and other trace gases). These will be run for a year in a participant's house.
- Sham air cleaner — DEVICEThe sham intervention is two sham air cleaners that have the internal HEPA and carbon filters removed, but which will run normally, including similar noise, airflow, and overall appearance compared to active air cleaners, thus blinding participants to filter status. These will be run for a year in a participant's house.
Study Details
This is a multi-center randomized, sham-controlled clinical trial to determine the effectiveness of an air cleaner intervention aimed at improving indoor air quality on reducing COPD exacerbation risk and improving quality of life, functional status, rescue medication use.
Key Dates
- Start date
- May 24, 2024
- Status verified
- Aug 2025
- Primary completion
- Aug 31, 2029
- Completion
- Nov 30, 2029
Study Design
- Enrollment
- 770 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- PREVENTION
Arms
- Experimental: Active air cleanerThe active arm will receive two active air cleaners with high efficiency particulate air (HEPA) filters which remove particulate matter (PM), as well as activated carbon filters to remove Nitrogen Dioxide (NO2) and other trace gases.
- Sham Comparator: Sham air cleanerThe sham control treatment arm will receive two sham air cleaners that have the internal HEPA and carbon filters removed, but which will run normally, including similar noise, airflow, and overall appearance compared to active air cleaners, thus blinding participants to filter status.
Primary Outcome Measure
St. George's Respiratory Questionnaire (SGRQ) [ Time Frame: baseline and 3, 6, 9, and 12 months after baseline ]
Central Contacts
- Stephan Ehrhardt, MD, PhD(410) 502-3872
Locations (11)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Alabama, Lung Health Center | Birmingham | Alabama | 35233 | James Michael Wells, MD (PRINCIPAL_INVESTIGATOR) |
| University of California, Los Angeles | Los Angeles | California | 90095 | Igor Barjaktarevic, MD (PRINCIPAL_INVESTIGATOR) |
| University of Iowa | Iowa City | Iowa | 52242 | Alejandro Comellas, MD (PRINCIPAL_INVESTIGATOR) |
| Johns Hopkins | Baltimore | Maryland | 21224 | |
| University of Maryland | Baltimore | Maryland | 21201 | William Grier, MD (PRINCIPAL_INVESTIGATOR) |
| Tidal Health | Salisbury | Maryland | 21801 | Robert Chasse, MD (PRINCIPAL_INVESTIGATOR) |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | Mary Rice, MD (PRINCIPAL_INVESTIGATOR) |
| University of Michigan | Ann Arbor | Michigan | 48109 | Meilan Han, MD (PRINCIPAL_INVESTIGATOR) |
| Dartmouth Hitchcock | Lebanon | New Hampshire | 03756 | Laura Paulin, MD (PRINCIPAL_INVESTIGATOR) |
| Cleveland Clinic | Cleveland | Ohio | 44195 | Russel Bowler, MD (PRINCIPAL_INVESTIGATOR) |
| Reading Hospital | West Reading | Pennsylvania | 19611 | Luis Murillo, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Birmingham, AL
Related Studies
- Quest to Analyze One Thousand Humans MeditatingEnrolling By Invitation · Tobias Moeller-Bertram · Palm Desert, California
- Effectiveness of the WearME System for COPD Severity and Respiratory FunctionRecruiting · LASARRUS Clinic and Research Center · Baltimore, Maryland
- A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)PHASE3 · Recruiting · AstraZeneca · Cullman, Alabama
- A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)PHASE3 · Recruiting · AstraZeneca · Foley, Alabama